Share Twitter LinkedIn Facebook Email Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency elaborates on the importance of biomarker selection trials. Biomarker trials may help guide prostate cancer patients respond to therapies.
Overview of SYNC-T Technology from Syncromune in Prostate Cancer Treatment – Charles Link, MD Prostate 2 Mins Read
Pioneering Advances in Non-Metastatic Prostate Cancer: Navigating ARPIs and Precision Diagnostics for Tailored Treatment [39 SLIDES] Prostate 5 Mins Read
Promontory Therapeutics: PT-112 triggers organelle stress and ribosomal inhibition Prostate 2 Mins Read
